Ignite Creation Date:
2024-05-06 @ 1:04 AM
Last Modification Date:
2024-10-26 @ 10:59 AM
Study NCT ID:
NCT01728285
Status:
COMPLETED
Last Update Posted:
2012-11-19
First Post:
2012-11-02
Brief Title:
Compliance to the Treatment With GRAZAX Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis
Sponsor:
ALK-Abelló AS
Organization:
ALK-Abelló AS
Study Overview
Official Title:
A Multicentric Open Randomised Cross-over Phase III Trial Assessing the Treatment Compliance With GRAZAX in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis
Status:
COMPLETED
Status Verified Date:
2012-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GT-17
Brief Summary:
Adherence to treatment is crucial to the efficacy of sublingual immunotherapy of allergic diseases GRAZAX is a registered drug in Europe with established efficacy in the treatment of allergic rhinitis which has to be taken daily by patients This study was aimed to establish if a device with the characteristics of a mechanical dispenser Memozax could improve adherence to treatment in subjects with hay fever due to allergy to grass
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-004820-35 | EUDRACT_NUMBER | None | None |